TG Therapeutics is conducting two studies to evaluate the safety of Briumvi (ublituximab-xiiy) in pregnant and breastfeeding MS patients. The PROVIDE study examines Briumvi levels in breast milk and its potential impact on nursing infants, while a pregnancy registry will monitor health outcomes for mothers and babies exposed to the drug during pregnancy. These studies aim to provide data for better-informed medical decisions regarding the use of Briumvi in these populations.
